Notice of Results

23 August 2016

PureTech Health plc

Notice of Half-Yearly Results

PureTech Health plc ("PureTech", LSE: PRTC), a cross-disciplinary biotech company tackling fundamental healthcare needs in disruptive ways, expects to announce its half-yearly results for the six months ended 30 June 2016 at 7.00am BST on Wednesday 7 September 2016.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biotech company focused on areas of growing scientific and technical insights that are at an important inflection point, including the central nervous, gastro-intestinal and immune systems, and the interactions and signalling between them. PureTech has approximately 20 clinical studies across its pipeline targeting multi-billion dollar market opportunities, including five human proof-of-concept studies and multiple pivotal or registration study readouts expected in the next two years. While inevitably some technologies will not advance to commercialisation, PureTech's approach mitigates risk as most of the cash resides on a PureTech parent company level, allowing PureTech to build value and divert cash to its most successful programmes as milestones are achieved. PureTech has over 220 patents and patent applications. PureTech's leading team and board, along with an advisory network of more than 60 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. With healthcare undergoing major transformation, PureTech believes it is well positioned to develop and launch medicines for the 21st century. For more information, visit www.puretechhealth.com and connect with us on Twitter.

Enquiries